3-methylquercetin and Osteoarthritis--Knee

3-methylquercetin has been researched along with Osteoarthritis--Knee* in 1 studies

Other Studies

1 other study(ies) available for 3-methylquercetin and Osteoarthritis--Knee

Article	Year
Isorhamnetin attenuates osteoarthritis by inhibiting osteoclastogenesis and protecting chondrocytes through modulating reactive oxygen species homeostasis. Journal of cellular and molecular medicine, 2019, Volume: 23, Issue:6 Increasing evidence indicates that osteoarthritis (OA) is a musculoskeletal disease affecting the whole joint, including both cartilage and subchondral bone. Reactive oxygen species (ROS) have been demonstrated to be one of the important destructive factors during early-stage OA development. The objective of this study was to investigate isorhamnetin (Iso) treatment on osteoclast formation and chondrocyte protection to attenuate OA by modulating ROS. Receptor activator of nuclear factor-kappa B ligand (RANKL) was used to establish the osteoclast differentiation model in bone marrow macrophages (BMMs) in vivo. H Topics: Animals; Bone Resorption; Chondrocytes; Homeostasis; Male; Mice; Mice, Inbred C57BL; Mitogen-Activated Protein Kinases; NF-kappa B; NFATC Transcription Factors; Osteoarthritis, Knee; Osteogenesis; Protective Agents; Quercetin; Reactive Oxygen Species; Signal Transduction	2019

Article

Year

Isorhamnetin attenuates osteoarthritis by inhibiting osteoclastogenesis and protecting chondrocytes through modulating reactive oxygen species homeostasis.

Journal of cellular and molecular medicine, 2019, Volume: 23, Issue:6

Increasing evidence indicates that osteoarthritis (OA) is a musculoskeletal disease affecting the whole joint, including both cartilage and subchondral bone. Reactive oxygen species (ROS) have been demonstrated to be one of the important destructive factors during early-stage OA development. The objective of this study was to investigate isorhamnetin (Iso) treatment on osteoclast formation and chondrocyte protection to attenuate OA by modulating ROS. Receptor activator of nuclear factor-kappa B ligand (RANKL) was used to establish the osteoclast differentiation model in bone marrow macrophages (BMMs) in vivo. H

Topics: Animals; Bone Resorption; Chondrocytes; Homeostasis; Male; Mice; Mice, Inbred C57BL; Mitogen-Activated Protein Kinases; NF-kappa B; NFATC Transcription Factors; Osteoarthritis, Knee; Osteogenesis; Protective Agents; Quercetin; Reactive Oxygen Species; Signal Transduction

2019